Treatment of dry, age-related macular degeneration by epidermal growth factor

Epidermal growth factor for treatment of non-exudative age-related macular degeneration

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12733334

Enrollment

Registered

2020-05-29

Start date

2020-04-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-exudative age-related macular degeneration Eye Diseases

Interventions

Participants will be randomly allocated to study or control groups using a random number selection method. For each study participant of the study group, the eye with the worse best-corrected visual

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age of 50 + years 2. Pseudophakia 3. Presence of geographic atrophy 4. Normal intraocular pressure 5. Lack of any other ocular disease except for age-related macular degeneration, and absence of any malignancy

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Size of geographic atrophies measured on fundus images obtained by optical coherence tomography at baseline, one month, three months and six months after baseline	—

Secondary

Measure	Time frame
At baseline, one month, three months and six months after baseline: 1. Visual acuity measured using by ophthalmologists or optometrists as best corrected visual acuity under standardized conditions and using modified Early Treatment of Diabetic Retinopathy Study (ETDRS) charts (Light House Low Vision Products, New York, NY) at a distance of 4 meters. If the optotypes cannot be read at a distance of 4m, one will continue with optotypes held at a distance of 1m. If the optotypes cannot be read at that distance the ability of finger counting and the detectability of hand movements at a distance of 1m or 50cm will be tested. If hand movements cannot be seen, the light perception with correct or incorrect projection will be assessed	—

Measure

Time frame

At baseline, one month, three months and six months after baseline: 1. Visual acuity measured using by ophthalmologists or optometrists as best corrected visual acuity under standardized conditions and using modified Early Treatment of Diabetic Retinopathy Study (ETDRS) charts (Light House Low Vision Products, New York, NY) at a distance of 4 meters. If the optotypes cannot be read at a distance of 4m, one will continue with optotypes held at a distance of 1m. If the optotypes cannot be read at that distance the ability of finger counting and the detectability of hand movements at a distance of 1m or 50cm will be tested. If hand movements cannot be seen, the light perception with correct or incorrect projection will be assessed

—

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026